Skip to content
OpenCapital
Get started

Incyte INCY MINJUVI/MONJUVI — Total revenues

Other product segments

JAKAFI
$757.76M+6.8%
OPZELURA
$143.02M+20.5%
JAKAVI Royalty Revenues
$105.56M+14.6%
NIKTIMVO
$55.09M+305%
ZYNYZ
$41.39M+1,276%
OLUMIANT Royalty Revenues
$36.41M+18.2%
ICLUSIG
$35.46M+20.0%
PEMAZYRE
$22.54M+22.3%
Milestone and contract revenues
$17M—
TABRECTA Royalty Revenues
$5.98M-6.7%
Other product royalty revenues
$3.25M+156%

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYRevlimid — Total Revenues
$349M-62.7%
Bristol-Myers Squibb logo
BMYOpdivo — Total Revenues
$2.15B-5.3%
Evolus logo
EOLSJeuveau — Total net revenues
$66.02M-3.0%
BioMarin Pharmaceuticals logo
BMRNVIMIZIM — Total revenues
$210.2M+11.6%
Gilead Sciences logo
GILDGenvoya — Total revenues
$264M-27.5%
Bristol-Myers Squibb logo
BMYOpdivo Qvantig — Total Revenues
$163M+1,711%

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.7%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$23.32B+74.2%
Enterprise value$19.89B+73.4%
P/E16.3×+0.9×
P/S4.4×+1.4×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp
FCF margin28.2%+19.7pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0×0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's minjuvi/monjuvi — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's MINJUVI/MONJUVI — total revenues?
Incyte (INCY) reported MINJUVI/MONJUVI — total revenues of $49.23M in Q1 2026.
How has Incyte's MINJUVI/MONJUVI — total revenues changed year-over-year?
Incyte's MINJUVI/MONJUVI — total revenues increased by 66.6% year-over-year, from $29.55M to $49.23M.
What is the long-term trend for Incyte's MINJUVI/MONJUVI — total revenues?
Over 3 years (2022 to 2025), Incyte's MINJUVI/MONJUVI — total revenues has grown at a 94.5% compound annual growth rate (CAGR), from $19.65M to $144.58M.
What does MINJUVI/MONJUVI — total revenues mean?
This metric represents the total gross revenue generated from the sale and commercialization of the Monjuvi/Minjuvi product line, a therapeutic agent used in the treatment of diffuse large B-cell lymphoma. It reflects the market adoption, pricing power, and clinical demand for this specific oncology asset within the company's broader portfolio. Revenue recognition is typically tied to product shipments and contractual arrangements with distributors or partners.